Expression of epidermal growth factor receptors (EGFRs) has been detected in several malignant tumour types, including breast (Nicholson et al., 1991) , ovarian (Kohler et al., 1992) , lung and glial tumours (Chaffenet et al., 1992; Fleming et al., 1992) . EGFR overexpression correlates with poor cellular differentiation (Bolla et al., 1992) , which is in turn a marker for poor prognosis in lymph node-negative breast cancer (Nicholson et al., 1991) , non-small-cell lung cancer (Veale et al., 1993) and superficial bladder cancer (Smith et al., 1989; Neal et al., 1990) . In breast cancer cells, increased expression correlates with reduced oestrogen receptor (ER) levels (Bilous et al., 1992) , and such an increase is associated with tamoxifen resistance (Nicholson et al., 1989) . Overexpression of EGFR is also associated with the multidrug resistance (MDR) phenotype (Shin et al., 1991) . There is therefore potential to exploit the difference between EGFR expression in normal and MDR-positive, malignant cells in order to target treatment to tumours which may respond poorly to chemotherapy (Harris, 1990) .
We have assessed the toxicity of a chimeric cytotoxin composed of two independent domains: (i) transforming growth factor a (TGF-o) and (ii) PE40, a 40 kDa segment of Pseudomonas exotoxin (PE). The toxicity of multidomain PE is abolished when the cell targeting moiety is removed to yield PE40, which can neither bind to nor enter cells (Pastan & FitzGerald, 1989) . Conjugating TGF-a to PE40 restores cell-binding activity, allowing selective entry of TGF-oc-PE40 (TP40) into EGFR-positive cells. Normal tissue expressing low levels of EGFR may therefore be less susceptible to toxicity. We have tested this hypothesis by determining the toxicity of TP40 to human breast cancer and lung cancer cell lines expressing different levels of EGFR. P-glycoprotein (Pgp)-positive cell lines were also included in the study to determine whether MDR confers cross-resistance to the chimeric toxin. The effects of the MDR modifiers tamoxifen (Ramu et al., 1984; Kirk et al., 1993a,b) , verapamil (Tsuruo et al., 1981) and cyclosporin A (Twentyman et al., 1987) on TP40 toxicity were also investigated; previous studies have suggested that verapamil may enhance the toxicity of chimeric toxins by altering PE40 processing in endosomes (Lyall et al., 1987; Jaffrezou & Laurent, 1993) .
Materials and methods
Cell lines and tissue culture The panel of cell lines used comprised eight human breast cancer, four small-cell lung cancer (SCLC) and nine non-which has mdrl levels at least 100-fold higher than its wildtype parental cell line, SI (Baas et al., 1990; F. Baas, personal communication) ; and (ii) MCF-7Adr (Batist et al., 1986) , derived from the human breast cancer cell line MCF-7 (Soule et al., 1973) by chronic exposure to adriamycin. Two strains of MCF-7 cells were used: an early-passage strain (MCF-7EP; passage 50-60) and a late-passage strain (MCF-7LP; passage >300) in order to monitor changes in receptor status and drug sensitivity during long-term growth in vitro. S1 and S1/1.l cells were kindly provided by F. Baas (Mosmann, 1983; Carmichael et al., 1987) .
Aliquots of MTT (50 tLI, 2 mg ml-') were dispensed into all wells and the cells incubated for a further 4 h. Plates were inverted to discard medium and formazan crystals were solubilised in 100yl of DMSO with 25 tlI of glycine buffer (0.1 M glycine/0.1 M sodium chloride, pH 10.5; Plumb et al., 1989) . Plates were agitated for 5 min, and optical densities determined immediately at 540 nm using a Titertek Multiskan Plus MKII ELISA plate reader. Data were stored and processed on a Macintosh SE/30 microcomputer.
Receptor assays Cells ( 108) in exponential growth phase, harvested by trypsinisation and washed three times with PBS, were resuspended in 4 ml of ice-cold homogenisation buffer (20 mM HEPES, 1.5 mM EDTA, 0.5 mM PMSF, 1 mM benzamidine, 10 ng ml-' ovomucoid, pH 7.4) and allowed to stand on ice for 30 min. Cells were lysed by homogenisation (30 strokes in a glass-glass homogeniser) on ice, centrifuged (3,000 r.p.m., 10 min, 4'C) to pellet nuclei and unbroken cells, and the resulting supernatants centrifuged at 100,000g for 45 min at 4'C. Supernatants (cytosolic extracts) were removed and supplemented with ice-cold dithiothreitol (200 mM) to a final concentration of 2 mM. Membrane pellets were rinsed twice with 0.5 ml of ice-cold membrane resuspension buffer (50 mM Tris, 150 mM sodium chloride, pH 7.4) then resuspended by gentle pipetting in 1. TP40 ICo values determined in the presence and absence of modifiers were compared using Student's paired two-tail ttest. Correlations between EGFR and ER levels, and between cellular EGFR levels and sensitivity to TP40, were analysed by calculating Kendall's coefficient of rank correltion (X); significance levels (P, one-tailed test) determined from Xr are quoted in the text.
Results

EGFR and ER levels
EGFR levels ranged from 0 to 4,480 fmol mg-' (Table I) .
For breast cancer cell lines, an inverse relationship (P = 0.01) was observed between EGFR and ER levels (Figure 1 Effects of EGF on growth of lung and breast cancer cell lines Marked variability was observed between the effects of EGF (0.1-300 ng ml-') on the growth of breast (Figure 2a ) and lung cancer cell lines (Figure 2b ). Growth of highly EGFRpositive MDA-468 cells was inhibited 54% by 10 ng ml-' EGF, while 100 ng ml-' EGF stimulated MCF-7Adr cell growth by 22%. Stimulation of SI, S1/1.1 (data not shown) and NCI-H 226 cell growth occurred at 30-100ngml-' EGF. These cell lines expressed relatively high levels of EGFR (-350-500 fmol mg-'), however NCI-H 322 and NCI-H 841, which also expressed high levels (575 and 723 fmol mg-' respectively), were unaffected by EGF treatment. No effect on other lung cancer cell lines that expressed low levels of EGFR (data not shown) was observed.
TP40 toxicity TP40 was toxic to all cell lines tested, with a 13,000-fold range in IC50 values observed (Table I) . NCI-H 249, NCI-H 522 and NCI-H 526 cells, which expressed low levels of EGFR (0-10 fmol mg-'), were most resistant to TP40 (IC50 = 35,000-180,000 pM), while MDA-468 cells, which expressed the highest level detected (4,480 fmol mg-'), were highly sensitive (IC50 = 22 pM). Similarly, NCI-H 226, NCI-H 322, NCI-H 841 and A549 cells, which were also highly EGFR positive (566-723 fmol mg-'), were very sensitive to TP40, with IC50 values of 14-46 pM. This trend is illustrated in Figure 3 , which shows TP40 IC50 values plotted as a function of EGFR levels for the panel of breast and lung cancer cell lines. A correlation (P = 0.01) was observed, indicating an inverse relationship between TP40 IC50 values and EGFR levels. This correlation was weakened by results obtained using NCI-H 460 and (early and late passage) MCF-7 cells which were sensitive to TP40 but expressed very low levels of EGFR (Table I) , and masking these values gave a stronger correlation (P = 0.005).
Lung Effects of modifiers on TP40 toxicity Figure 4a and b shows the effects of 0, 10, 100 and 500 ng ml-' .EGF on TP40 toxicity to SI and Sl/1.1 cells.
EGF caused a concentration-dependent rightward shift in the dose-response curves, indicating antagonism of TP40 toxicity. This protective effect was observed with all cell lines tested, and IC50 values for TP40 determined in the absence and presence of the highest concentration of EGF used (500 ng ml-') are listed in Table II . TP40 toxicity was reduced 81-(NCI-H 226) to 240-fold (SI/1.1). The degree of protection (MF) at 10 ng ml-' (Figure 5a ) and 100 ng ml-' EGF ( Figure Sb) was plotted as a function of EGFR levels for eight lung and breast cancer cell lines, and strong correlations (r = -0.8 and -0.9 respectively) were observed at each concentration, while the degree of protection at 500 ng ml-' EGF did not correlate with EGFR levels (r = 0.01, data not shown). At IO and 100 ng ml-' EGF, therefore, cell lines expressing low levels (<50 fmol mg-1) of EGFR were most highly protected from TP40 toxicity. The MDR-modifying agents tamoxifen, verapamil and cyclosporin A did not alter TP40 toxicity to any cell line tested (Table II) , although verapamil has previously been shown to enhance toxicity of a different PE conjugate, EGF-PE, to human KB cells (Lyall et al., 1987; Jaffrezou & Laurent, 1993) .
Discussion
An inverse relationship was observed between ER and EGFR levels for the breast cancer cell lines, similar to results on human tumour biopsies previously published (Sainsbury et al., 1985; Bilous et al., 1992; Bolla et al., 1992) . EGFR-positive cells may have a growth advantage over hormone-dependent, EGFR-negative cells and outgrow ER-positive cells both in vitro and in vivo. This effect is apparent with wild-type MCF-7 cells, early-passage cells being EGFR-negative and highly ER-positive, while later passage cells express low levels of EGFR and reduced levels of ER. SCLC cell lines generally grow in an anchorageindependent manner and do not express EGFR, however loss of the non-adherent phenotype may occur during continuous growth in vitro. Such loss was correlated in our panel of cell lines with increased expression of EGFR. Gamou et al. 'EGF was added to cells at 500 ng ml-1. bTamoxifen was added to cells at 1 t4M (MCF-7 cells) or 1O tLM (remaining cell lines). cCyclosporin A (CsA) and verapamil were added to cells at 5 AM. dWhere MF= 1, P =0.05-1. *P =0.01-0.05, **P =0.001 -0.01, ***P =0.0001-0.001. Filmus et al. (1985) , and also demonstrated with the highly EGFR-positive cell line, A431 (Gill & Lazar, 1981) . Kaplan et al. (1990) , working with MDA-468 cells, have suggested that inhibition is an artefact of in vitro systems; EGF strongly stimulates glucose metabolism in highly EGFR-positive cells, thereby depleting the medium of this sugar and leading to cell death through glucose starvation.
We have assessed TP40 toxicity to a panel of cell lines, which displayed a 13,000-fold range in sensitivity. Cell lines most resistant to TP40 expressed little or no EGFR, while those most sensitive generally expressed high levels of EGFR. This correlation between EGFR expression and TP40 sensitivity for cells which are highly resistant or highly sensitive to TP40 supports the hypothesis that TP40 enters cells via binding of the TGF-a moiety to EGFR. Additional evidence is provided by the dose-dependent protection from toxicity observed in the presence of EGF. EGF may protect cells from TP40 toxicity either directly, through competition for binding to EGFR, and/or by down-regulating EGFR expression. At 10 and 100 ng ml-' EGF, cellular expression of EGFR correlated inversely with the degree of protection from toxicity, indicating that cell lines expressing low levels of EGFR were most highly protected. For cells expressing little EGFR, these concentrations of EGF apparently reduced binding of TP40 to levels insufficient to cause toxicity. Higher levels of EGF would presumably be required to prevent binding of TP40 to cells with high EGFR levels. Normal tissue EGFR expression is 5-50 fmol mg' in nonsquamous tissues (Ozawa et al., 1988) Lyall et al. (1987) found that verapamil enhanced toxicity of another PE conjugate, EGF-PE, to human KB cells, and indeed many MDR modulators have also been shown to enhance toxicity of ligand-toxin conjugates (Jaffrezou & Laurent, 1993) . Verapamil may sensitise cells to PE conjugates by altering the pH within endosomes, thereby enhancing translocation of the toxin to the cytosol (Lyall et al., 1987) . However, Jaffrezou and Laurent (1993) suggest that a common mechanism, such as altered lipid metabolism, may account for enhanced toxicity of both ligand-toxin conjugates and drugs associated with MDR. Such sensitisation was not observed in the present study, indicating that this effect may be specific either to the cell type or to the PE conjugate used.
In conclusion, the recombinant cytotoxic protein TP40 was highly toxic to EGFR-positive cells at picomolar concentrations, while EGFR-negative cell lines tended to be more resistant. Tumour cells refractory to conventional chemotherapy frequently overexpress EGFR (Smith et al., 1989; Nicholson et al., 1991) and may therefore be sensitive to treatment with TP40. Low EGFR-expressing cells were selectively protected from TP40 toxicity by EGF (10-100 ng ml ), and EGF may have a role in combination with TP40 to target highly EGFR-positive tumours in vivo. Expression of Pgp was not associated with resistance to TP40, which may also be effective in the treatment of MDRpositive tumours.
